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A B S T R A C T
Cholestane-3β,5α,6β-triol (3β,5α,6β-triol) is formed from cholestan-5,6-epoxide (5,6-EC) in a reaction catalysed
by cholesterol epoxide hydrolase, following formation of 5,6-EC through free radical oxidation of cholesterol. 7-
Oxocholesterol (7-OC) and 7β-hydroxycholesterol (7β-HC) can also be formed by free radical oxidation of
cholesterol. Here we investigate how 3β,5α,6β-triol, 7-OC and 7β-HC are metabolised to bile acids. We show, by
monitoring oxysterol metabolites in plasma samples rich in 3β,5α,6β-triol, 7-OC and 7β-HC, that these three
oxysterols fall into novel branches of the acidic pathway of bile acid biosynthesis becoming (25R)26-hydro-
xylated then carboxylated, 24-hydroxylated and side-chain shortened to give the ﬁnal products 3β,5α,6β-tri-
hydroxycholanoic, 3β-hydroxy-7-oxochol-5-enoic and 3β,7β-dihydroxychol-5-enoic acids, respectively. The in-
termediates in these pathways may be causative of some phenotypical features of, and/or have diagnostic value
for, the lysosomal storage diseases, Niemann Pick types C and B and lysosomal acid lipase deﬁciency. Free
radical derived oxysterols are metabolised in human to unusual bile acids via novel branches of the acidic
pathway, intermediates in these pathways are observed in plasma.
1. Introduction
The oxysterols 7-oxocholesterol (7-OC, for systematic names see
Supplemental Table S1), 7β-hydroxycholesterol (7β-HC), 5α,6-epox-
ycholesterol (5α,6-EC), 5β,6-epoxycholesterol (5β,6-EC) and choles-
tane-3β,5α,6β-triol (3β,5α,6β-triol) have for many years been thought
of as autoxidation artefacts formed ex vivo from cholesterol during
sample handling [1-3]. This view is now changing with the realisation
that (i) 7-OC can be formed enzymatically from 7-dehydrocholesterol
(7-DHC) [4], (ii) 7β-HC and 7-OC can be interconverted in enzyme
catalysed reactions [5-9], while (iii) the 5α,6-EC adduct dendrogenin A
(DDA) is present in tissue [10], (iv) 5,6-EC is hydrolysed by the enzyme
cholesterol epoxide hydrolase (ChEH) to 3β,5α,6β-triol which itself is
oxidised by hydroxysteroid dehydrogenase (HSD) 11B2 to 3β,5α-di-
hydroxycholestan-6-one (3β,5α-diHC-6O, also called 6-oxocholestan-
3β,5α-diol) found at elevated levels in breast cancer tissue [11], and (v)
high levels of 7-OC and 3β,5α,6β-triol are characteristic of the lyso-
somal storage diseases Niemann-Pick types A, B, C1 and C2 (NPA, NPB,
NPC) and lysosomal acid lipase deﬁciency (LALD) [12-18]. In these
inborn errors of metabolism, characterised by the accumulations of
multiple lipid species including the build-up of lysosomal cholesterol, it
is likely that 7-OC and 5,6-EC, the precursor of 3β,5α,6β-triol, are
formed via free radical reactions (Fig. 1). Importantly, 7-OC, 7β-HC,
5α,6-EC and 3β,5α,6β-triol are precursors of biologically active mole-
cules, including 25-hydroxy-7-oxocholesterol (25H,7O-C) and 26-hy-
droxy-7-oxocholesterol (26H,7O-C) which are ligands to the Hedgehog
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Abbreviations
ACOT acyl-CoA thioesterases
ACOX2 acyl-coenzyme A oxidase 2
AMACR alpha-methylacyl-CoA-racemase
BACS bile acyl CoA-synthetase
ChEH cholesterol epoxide hydrolase
ChOx cholesterol oxidase
CYP cytochrome P450
DBP D bifunctional protein
DDA dendrogenin A
Hh Hedgehog
HSD hydroxysteroid dehydrogenase
GlcNAc N-acetylglucosamine
GP Girard P reagent
LALD lysosomal acid lipase deﬁciency
LC-MS liquid chromatography mass spectrometry
MRM multiple reaction monitoring
MSn mass spectrometry with multistage fragmentation
NPA Niemann-Pick disease type A
NPB Niemann-Pick disease type B
NPC Niemann-Pick disease type C
RICs reconstructed ion chromatograms
SLOS Smith-Lemli-Opitz syndrome
Smo Smoothened
SPCx sterol carrier protein x
3β-HCA 3β-hydroxycholest-5-en-(25R)26-oic acid
3βH,7O-CA 3β-hydroxy-7-oxocholest-5-en-(25R)26-oic acid
3βH,7O-Δ5-BA 3β-hydroxy-7-oxochol-5-enoic acid
3β,5α-diHC-6O 3β,5α-dihydroxycholestan-6-one
3β,5α,6β-triHBA 3β,5α,6β-trihydroxycholanoic acid
3β,5α,6β-triHCa 3β,5α,6β-trihydroxycholestan-(25R)26-oic acid
3β,5α,6β-triol cholestane-3β,5α,6β-triol
3β,5α,6β,24-tetraHCa 3β,5α,6β,24-tetrahydroxycholestan-26-oic
acid
3β,5α,6β,26-tetrol cholestane-3β,5α,6β,(25R)26-tetrol
3β,7α-diHCA 3β,7α-dihydroxycholest-5-en-(25R)26-oic acid
3β,7β-diHCA 3β,7β-dihydroxycholest-5-en-(25R)26-oic acid
3β,7β-diH-Δ5-BA 3β,7β-dihydroxychol-5-enoic acid
3β,7β,24-triHCA 3β,7β,24-trihydroxycholest-5-en-26-oic acid
3β,24-diH,7O-CA 3β,24-dihydroxy-7-oxocholest-5-en-26-oic acid
5α,6-EC 5α,6-epoxycholesterol
5β,6-EC 5β,6-epoxycholesterol
7-DHC 7-dehydrocholesterol
7-OC 7-oxocholesterol
7α-HCO 7α-hydroxycholest-4-en-3-one
7α-HC 7α-hydroxycholesterol
7αH,3O-CA 7α-hydroxy-3-oxocholest-4-en-(25R)26-oic acid
7β-HC 7β-hydroxycholesterol
7β,26-diHC 7β,26-dihydroxycholesterol
24S-HC 24S-hydroxycholesterol
25-HC 25-hydroxycholesterol
25H,7O-C25-hydroxy-7-oxocholesterol
26-HC (25R)26-hydroxycholesterol
26H,7O-C26-hydroxy-7-oxocholesterol.
Fig. 1. Free radical formation of 7α-HC, 7β-HC, 7-OC and 5,6-EC [34]. The reactions shown in blue boxes and by blue arrows are enzyme catalysed. CYP, cytochrome
P450; HSD, hydroxysteroid dehydrogenase; ChEH, cholesterol epoxide hydrolase; LOO., lipidperoxy radical; LO., lipidalkoxy radical; LOH, lipidhydroxide; LOOH
lipidhydroperoxide; RH, hydrogen donor.
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(Hh) pathway oncoprotein Smoothened (Smo) [19]; 7β,26-dihydrox-
ycholesterol (7β,26-diHC), a ligand to the nuclear receptor RORγt [20];
DDA a tumour suppressor [21] and both DDA and dendrogenin B have
potent proliferative eﬀects in neural stem cells [10]; and the oncome-
tabolite and glucocorticoid receptor ligand 3β,5α-diHC-6O [11]. Ac-
cepting that the 5,6-epoxides and 7-oxidised sterols are formed in vivo,
interest now shifts to investigating how they are metabolised. With
respect to 7-OC, we have recently reported that in patients with the
recessive congenital disorder Smith-Lemli-Opitz syndrome (SLOS) 7-OC
can be converted to 7β-hydroxy bile acids and ultimately conjugated
with N-acetylglucosamine (GlcNAc) [22-25]. A similar pathway may
also be operative in patients with NPC disease where 7-OC is also ele-
vated and the same GlcNAc conjugated bile acids have been identiﬁed
[26]. Patients with NPC, NPB or NPA show elevated 3β,5α,6β-triol in
plasma, presumably derived from free radical oxidation of cholesterol
to 5,6-EC followed by hydrolysis to the triol by ChEH (Fig. 1) [27].
Clayton and colleagues and Ory and colleagues have now both identi-
ﬁed 3β,5α,6β-trihydroxycholanoic acid (3β,5α,6β-triHBA) as the bile
acid product of 3β,5α,6β-triol metabolism [28,29]. An alternative route
for metabolism of 3β,5α,6β-triol is oxidation to the oncometabolite
3β,5α-diHC-6O [11].
Although the end products of 7-OC and 5,6-EC/3β,5α,6β-triol
metabolism have been deﬁned, the in vivo biochemical pathways gen-
erating these products have yet to be fully elucidated. To study further
the metabolism of 7-OC and 5,6-EC/3β,5α,6β-triol we took advantage
of plasma samples from patients where levels of these substrates are
particularly high. We ﬁnd that 7-OC, 7β-HC and 3β,5α,6β-triol fall into
new branches of the acidic pathway of bile acid biosynthesis and in
patient plasma where the concentration of these metabolites is high,
almost all the necessary intermediates to bile acids are observed. Build-
up of these intermediates may be responsible for some of the clinical
features of diseases where free radical oxidation of cholesterol is pre-
valent and their measurement may have diagnostic value.
2. Materials and methods
2.1. Materials
Oxysterol standards were from Avanti Polar Lipids Inc (Alabaster,
Al, USA), 3β,5α,6β-triHBA was prepared as in Ref. [29], other bile acid
standards were kindly donated by Dr Jan Sjövall of Karolinska Institute,
Stockholm, or as detailed in Griﬃths et al. [30]. Materials for liquid
chromatography – mass spectrometry (LC-MS) analysis were as in Refs.
[31,32].
Fig. 2. Derivatisation of (i) 3β-hydroxy-5-ene, and (ii) 3β,5α,6β-triol, containing sterols via oxidation with bacterial cholesterol oxidase (ChOx) and reaction with
[2H5]GP, and of (iii) 7-oxo-sterols by reaction with [2H0]GP in the absence of cholesterol oxidase. The reactions are illustrated for 7β-HC, 3β,5α,6β-triol and 7-OC,
respectively.
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Fig. 3. LC-MS reconstructed ion chromatograms (RICs) of oxidised/[2H5]GP derivatised oxysterols and bile acids in plasma from an NPB patient and NPB carrier.
RICs for (A) m/z 539.4368 corresponding to [M]+ ions of hydroxycholesterols (HC) and [M−H2O]+ ions of 3β,5α,6β-triol, (B) m/z 527.3640 corresponding to
[M]+ ions of dihydroxychol-5-enoic acids (diH-Δ5-BA) and [M−H2O]+ ions of 3β,5α,6β-triHBA, (C) m/z 555.4317 corresponding to [M]+ ions of dihydrox-
ycholesterols (diHC) and [M−H2O]+ ions of 3β,5α,6β,26-tetrol, (D) m/z 569.4110 corresponding to [M]+ ions of dihydroxycholest-5-en-26-oic acids (diHCA) and
[M−H2O]+ ions of 3β,5α,6β-triHCa, (E) m/z 585.4059 corresponding to trihydroxycholest-5-en-26-oic acids (triHCA) and [M−H2O]+ ions of 3β,5α,6β,24-
tetraHCa. The upper panels show RICs of NPB patient and lower panels NPB carrier plasma. Oxysterols with a the 3β,5α,6β-triol function are labelled in blue, those
with a 3β,7β-dihydroxy function in red. Concentrations are given in the righthand corner of chromatograms. GP derivatised oxysterols give syn and anti conformers,
which may or may not be chromatographically separated. For quantiﬁcation of 3β,5α,6β,26-tetrol and 3β,5α,6β,24-tetraHCa extended chromatographic gradients
were exploited as described in Griﬃths et al. [30].
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2.2. Patient samples
All participants or their parents/guardians provided informed con-
sent and the study was performed with institutional review board
approval (REC08/H1010/63) and adhered to the principles of the
Declaration of Helsinki.
Fig. 4. Formation and metabolism of 5,6-EC, 7β-HC and 7-OC. The enzymes catalysing the reactions are cholesterol epoxide hydrolase (ChEH), hydroxysteroid
dehydrogenase 11B1 (HSD11B1), HSD11B2, cytochrome P450 27A1 (CYP27A1), bile acyl CoA-synthetase (BACS), alpha-methylacyl-CoA-racemase (AMACR), acyl-
coenzyme A oxidase 2 (ACOX2), D bifunctional protein (DBP) and sterol carrier protein x (SPCx). For simplicity, the individual reactions catalysed by BACS, AMACR,
ACOX2, DBP and SPCx are omitted and carboxylic acids rather than CoA-thioesters are shown. The peroxisomal enzyme bile acid CoA thioesterase (ACOT) will
hydrolyse the CoA-thioesters to free acids [38,39].
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2.3. LC-MS methods
The LC-MS methods have been described in detail elsewhere
[30,31]. In brief, a charge-tagging method was adopted [31,32], where
sterols, including oxysterols and bile acids, with a 3β-hydroxy group
were oxidised with bacterial cholesterol oxidase (ChOx) to 3-oxo ana-
logues and derivatised with [2H5]-labelled Girard P (GP) reagent
(Fig. 2), then analysed by LC-MS at high mass-resolution (120,000 atm/
z 400, full-width at half-maximum height deﬁnition) with parallel
multistage fragmentation (MSn). Sterols with a natural oxo group were
derivatised with [2H0]GP reagent in the absence of cholesterol oxidase
and analysed together with the [2H5]GP-derivatised sterols in a single
LC-MS(MSn) run. Quantiﬁcation was by the isotope dilution method.
3. Results
3.1. GP derivatisation of 3β-hydroxy-5-enesterols, 3β,5α,6β-
trihydroxysterols and 7-oxosterols
Cholesterol oxidase from Streptomyces sp converts sterols with a 3β-
hydroxy-5-ene function to analogues with a 3-oxo-4-ene structure,
which are substrates for derivatisation with [2H5]GP (Fig. 2). The de-
rivatisation products give [M]+ ions in LC-MS analysis. Upon oxida-
tion/derivatisation of 3β,5α,6β-trihydroxysterols the 5α-hydroxy group
is labile with the result that these oxysterols becomes converted to
[2H5]GP-derivatives of a 6β-hydroxy-3-oxo-4-ene structure, i.e. the
[M−H2O]+ ion of the oxidised/derivatised triol [33]. 7-Oxosterols do
not require cholesterol oxidase treatment prior to [2H0]GP derivatisa-
tion and are hence evident as [M]+ ions in preparations in the absence
of enzyme (Fig. 2). GP-derivatised sterols containing a 3β,5α,6β-triol
function give characteristic MS3 spectra this allows their presumptive
identiﬁcation by LC-MS(MSn) in the absence of authentic standards.
This is also true for 7-oxo- and 3β,7β-dihydroxysterols [30].
3.2. Metabolism of 5,6-EC
Both 5α,6-EC and 5β,6-EC are converted in vivo by ChEH to
3β,5α,6β-triol [34,35] (Fig. 1) and both Mazzacuva et al. [28] and
Jiang et al. [29] have found 3β,5α,6β-triHBA to be a bile acid produced
by NPC patients in whom the 3β,5α,6β-triol is abundant. We thus
sought to conﬁrm these ﬁnding by analysis of NPC patient plasma
(n=3) and to identify the intermediates in the biochemical pathway
from 3β,5α,6β-triol to 3β,5α,6β-triHBA. 3β,5α,6β-triol is also reported
to be abundant in plasma samples from NPB and LALD patients [15-18],
so we similarly analysed plasma samples from patients with these dis-
orders (NPB, n= 3; LALD, n=2). We also analysed plasma samples
from carriers of these disorders (see Supplemental Table S1). To mini-
mise problems of ex vivo oxidation of cholesterol producing 5,6-EC
artefacts, cholesterol was removed from samples by reversed-phase
solid phase extraction as a ﬁrst step in sample preparation, conse-
quently 5,6-EC and 3β,5α,6β-triol, the latter of which may be formed
by ex vivo acid catalysed hydrolysis of 5,6-EC, are minimised in plasma
samples from healthy donors, including disease carriers (5,6-EC<0.5
ng/mL; 3β,5α,6β-triol < 3.5 ng/mL), see also Supplemental Table S1
which embraces data from the standard reference material NIST SRM
1950, prepared from plasma samples from 100 individuals between 40
and 50 years of age, whose ethnicity was representative of the US po-
pulation and which included an equal number of men and women [36].
However, upon analysis of patient plasma for 3β,5α,6β-triol, elevated
levels were found in NPC (range 31–53 ng/mL) and NPB (23.5–45.5 ng/
mL) samples (Supplemental Table S1, Fig. 3A) conﬁrming the results of
earlier studies [13,15-18], although the triol was only increased in one
of the LALD samples (3.5–7.5 ng/mL). The precursor of 3β,5α,6β-triol,
5,6-EC, was similarly elevated in NPC (1–2.5 ng/mL) plasma, although
in only one of the NPB (0.5–2 ng/mL) and LALD (0.5–1 ng/mL) plasma
samples. The product of 3β,5α,6β-triol metabolism, 3β,5α,6β-triHBA,
was found in NPC (1–3.5 ng/mL), NPB (1–2 ng/mL) and one of the two
LALD (0–1.5 ng/mL) plasma samples (Fig. 3B), but was absent from
controls and carriers (≤0.1 ng/mL). It is likely that 3β,5α,6β-triol is
converted to 3β,5α,6β-triHBA in a series of enzyme catalysed reactions,
like those operative in the acidic pathway of bile acid biosynthesis [37].
3.2.1. Acidic pathway
If 3β,5α,6β-triol falls into a branch of the acidic pathway of bile acid
biosynthesis the next metabolite, generated by the enzyme cytochrome
P450 (CYP) 27A1, should be cholestane-3β,5α,6β,(25R)26-tetrol
(3β,5α,6β,26-tetrol, Fig. 4). Although we do not have an authentic
standard of the tetrol, it was presumptively identiﬁed in plasma sam-
ples from patients with NPC (0.5–1.5 ng/mL) and NPB (1–1.5 ng/mL)
based on LC retention time, exact mass and MS3 spectrum, but was
absent from control and carrier plasma (Fig. 3C, see Figure 6G in Ref.
[30] for MS3 spectrum). Further, metabolism catalysed by CYP27A1
should lead to 3β,5α,6β-trihydroxycholestan-(25R)26-oic acid
(3β,5α,6β-triHCa). Evidence for the presence of 3β,5α,6β-triHCa in
plasma samples from patients with NPC (6–16 ng/mL), NPB
(31.5–47.5 ng/mL) and LALD (2–21 ng/mL) was again provided by LC
retention time, exact mass and MS3 spectra (see Figure 6D in Ref. [30]
for MS3 spectrum). 3β,5α,6β-triHCa was present at low levels in control
and carrier plasma (≤0.5 ng/mL, Fig. 3D). It is noteworthy that in the
separate patient groups the concentrations of this acid appears to reﬂect
those of the triol. However, the highest concentration of 3β,5α,6β-
triHCa in NPC plasma is only about half that of the lowest concentration
in NPB plasma. Interestingly, the concentration of 3β-hydroxycholest-5-
en(25R)26-oic (3β-HCA), 3β,7α-dihydroxycholest-5-en-(25R)26-oic
(3β,7α-diHCA) and 7α-hydroxy-3-oxocholest-4-en-(25R)26-oic
(7αH,3O-CA) acids, three cholestenoic acids of the conventional acidic
pathway, are also higher in the NPB plasma samples (3β-HCA,
300–648 ng/mL; 3β,7α-diHCA, 132–336 ng/mL; 7αH,3O-CA,
120.5–316 ng/mL) than in NPC (3β-HCA, 54.5–111 ng/mL; 3β,7α-
diHCA, 13.5–42 ng/mL; 7αH,3O-CA, 29.5–76 ng/mL) or controls and
carriers (3β-HCA, 53–143.5 ng/mL; 3β,7α-diHCA 10.5–35.5 ng/mL;
7αH,3O-CA, 43.5–69 ng/mL). Importantly, the initial metabolite of the
conventional acidic pathway, (25R)26-hydroxycholesterol (26-HC),
formed by CYP27A1 metabolism of cholesterol, was higher in NPB
plasma samples (40–68 ng/mL) samples than NPC (12–16 ng/mL),
LALD (7.5–11.5 ng/mL) or controls and carriers (16–28 ng/mL). These
trends were not observed for initial members of the neutral pathway of
bile acid biosynthesis i.e. 7α-hydroxycholesterol (7α-HC, NPB,
10–12.5 ng/mL; NPC, 12–35 ng/mL; LALD, 2.5–3 ng/mL; control/car-
rier, 1.5–13.5 ng/mL), the 24-hydroxylase pathway i.e. 24S-hydro-
xycholesterol (24S-HC, NPB, 9–34.5 ng/mL; NPC, 11.5–15.5 ng/mL;
LALD, 28.5–34.5 ng/mL; control/carriers, 7–13.5 ng/mL) or the 25-
hydroxylase pathway i.e. 25-hydroxycholesterol (25-HC, NPB,
1.5–2 ng/mL; NPC, 1–1.5 ng/mL; LALD<1 ng/mL, control/carriers,
0.5–1 ng/mL).
3.3. Shortening C27 to C24 bile acids
Side-chain shortening of 3β,5α,6β-triHCa is likely to proceed in the
peroxisome. This would involve formation of a CoA-thioester via the
enzyme bile acyl CoA-synthetase (BACS), its epimerisation at C-25 by
alpha-methylacyl-CoA-racemase (AMACR), dehydrogenation of the
side-chain between C-24 and C-25 by acyl-coenzyme A oxidase 2
(ACOX2), then hydration of the resultant double bond by peroxisomal
multifunctional enzyme type 2, also known as D bifunctional protein
(DBP), to give 3β,5α,6β,24-tetrahydroxycholestan-26-oic acid
(3β,5α,6β,24-tetraHCa) as the CoA thioester (in Fig. 4, for simplicity
the individual steps between 3β,5α,6β-triHCa and 3β,5α,6β,24-tet-
raHCa have been omitted and the free acids are shown rather than the
CoA thioesters). Using our oxidation/derivatisation method the free
acids are preferentially observed and, in the absence of an authentic
standard, 3β,5α,6β,24-tetraHCa was presumptively identiﬁed by LC
W.J. Griﬃths, et al. Free Radical Biology and Medicine xxx (xxxx) xxx–xxx
6
Fig. 5. LC-MS RICs or MRM chromatograms of [2H0]GP derivatised oxysterols and bile acids from NPB patient and NPB carrier plasma. RICs of (A) m/z 534.4054
corresponding to [M]+ ions of 7α-hydroxycholest-4-en-3-one (7α-HCO) and 7-OC, (B) m/z 550.4003 corresponding to [M]+ ions of dihydroxycholest-4-en-3-ones
(diHCO) and 26H,7O-C, and (E) m/z 522.3326 corresponding to [M]+ ions of hydroxy-3-oxochol-4-enoic acids (H,3O-Δ4-BA) and 3βH,7O-Δ5-BA. MRM chroma-
tograms of (C) m/z 564→ 485→426 speciﬁc for 3βH,7O-CA, and (D) m/z 580→ 501→442 speciﬁc for 3β,24-diH,7O-CA. The upper panels show chromatograms of
NPB patient and lower panels NPB carrier plasma. Oxysterols with a the 7-oxo function are labelled in red. Concentrations are given in the right-hand corner of
chromatograms. GP derivatised oxysterols give syn and anti conformers, which may or may not be chromatographically separated. For quantiﬁcation of 26H,7O-C an
extended chromatographic gradient was exploited as described in Griﬃths et al. [30].
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retention time, exact mass and MS3 spectrum in plasma samples from
NPC (0.5–2.5 ng/mL), NPB (2.5–4 ng/mL) and LALD (0.5–4.5 ng/mL,
see Supplemental Figure S5Q in Ref. [30]). There was no evidence for
3β,5α,6β,24-tetraHCa in control or carrier plasma (Fig. 3E). As with
3β,5α,6β-triHCa, the concentration of 3β,5α,6β,24-tetraHCa reﬂects
that of the triol within separate patient groups, but not between groups
where concentrations of the acids are higher in NPB plasma. The ulti-
mate C24 bile acid CoA thioester should be formed by beta-oxidation
through sterol carrier protein x (SPCx) after dehydrogenation by DBP
(HSD17B4). As indicated above, free bile acids are preferentially ob-
served with the current method and 3β,5α,6β-triHBA was detected in
NPC (1–3.5 ng/mL), NPB (1–2 ng/mL) and one of the two LALD
(0–1.5 ng/mL) patient samples, but not controls or carriers (≤0.1 ng/
mL) (Fig. 3B). A peroxisomal CoA thioesterase can catalyse the hy-
drolysis of bile acid CoA thioesters into free bile acids [38,39].
3.4. Metabolism of 7-OC and 7β-HC
The metabolism of 7-OC has been of interest to many investigators.
Lyons and Brown reported that it could be metabolised to 26H,7O-C by
CYP27A1 in HepG2 cells, while Heo et al. showed that 26H,7O-C and
the down-stream CYP27A1 metabolite 3β-hydroxy-7-oxocholest-5-en-
(25R)26-oic acid (3βH,7O-CA) could be formed by retinal pigment
epithelial cells [40,41]. An alternative route for metabolism of 7-OC is
reduction to 7β-HC by HSD11B1 as shown by Hult et al., Larsson et al.,
Mitic et al. and Schweizer et al. [5-8]. 7-OC itself can be formed via
radical reactions from cholesterol or enzymatically from 7-DHC by
CYP7A1 or from 7β-HC by HSD11B2 oxidation [4,9,34] (Fig. 1). We
have reported a metabolic pathway from 7-OC to 7-oxo- and 7β-hy-
droxy-Δ5-bile acids in SLOS patients where the 7-DHC concentrations
are high in plasma and tissue [22-25]. We next sought to investigate if
this pathway is active in other diseases where levels of 7-OC are ele-
vated.
Like 3β,5α,6β-triol, 7-OC is elevated in plasma of patients with ly-
sosomal storage disorders. Patients with NPC and NPB show elevated
levels of both 7-OC (NPC, 72.5–135.5 ng/mL; NPB 65.5–112.5 ng/mL,
Fig. 5A) and 7β-HC (NPC, 29.5–69 ng/mL; NPB, 19–54 ng/mL, Fig. 3A)
in plasma compared to controls and carrier (7-OC,< 8.5 ng/mL; 7β-
HC,< 2 ng/mL). In plasma from LALD patients 7-OC (9.5–20 ng/mL)
was just elevated but not 7β-HC (1.5–3.5 ng/mL). The ratio of 7-OC to
7β-HC was about 2.5 for the NPC (2.2 ± 0.3, mean ± standard de-
viation) and NPB (2.7 ± 0.7) patients, but much more variable for the
carriers (12.9 ± 5.7) and LALD (6.10) patients. Interestingly, the ratio
of 7-OC to 3β,5α,6β-triol was also about 2.5 for the NPC (2.2 ± 0.4),
NPB (2.5 ± 0.2) and LALD (2.7) patients, but more variable for the
carriers (3.3 ± 1.6). 7-OC and 7β-HC are interconverted by HSD11B1
and HSD11B2 and both may fall into branches of the acidic pathway of
bile acid metabolism (Fig. 4), giving the bile acids 3β,7β-dihydrox-
ychol-5-enoic (3β,7β-diH-Δ5-BA) and 3β-hydroxy-7-oxochol-5-enoic
(3βH,7O-Δ5-BA) acid as metabolic products (see Supplemental Table
S1). In fact, we observe almost all the necessary pathway intermediates
in NPC, NPB and LALD patient plasma in contrast to controls and car-
riers where intermediates are absent or minor.
3.4.1. Acidic pathway:- 7β-HC
Considering the metabolites of 7β-HC ﬁrst, authentic standards are
available for 7β-HC, 7β,26-diHC, 3β,7β-dihydroxycholest-5-en-(25R)
26-oic acid (3β,7β-diHCA) and 3β,7β-diH-Δ5-BA and each are chro-
matographically resolved from their 7α-epimers [42]. 7β,26-diHC was
absent from control and carrier plasma but was present in two of the
three NPC (0–1.5 ng/mL) and NPB (0–0.5 ng/mL) and one of the two
LALD (0–0.2 ng/mL) plasma samples (Fig. 3C). The further CYP27A1
metabolite, 3β,7β-diHCA, is a normal constituent of plasma from
healthy individuals (control and carriers, 3–5 ng/mL), but is greatly
elevated in NPC (40.5–229 ng/mL) and NPB (97–174 ng/mL) plasma
and to a lesser extent in LALD (11–52.5 ng/mL) plasma (Fig. 3D). We do
not have an authentic standard for 3β,7β,24-trihydroxycholest-5-en-26-
oic acid (3β,7β,24-triHCA), however, the 7α-epimer (3β,7α,24-triHCA)
is commercially available, this allows a presumptive, rather than deﬁ-
nitive, identiﬁcation of 3β,7β,24-triHCA based on exact mass, MS3
spectrum and retention time. The 7β-epimer is essentially absent from
control and carrier plasma (< 0.1 ng/mL), but present in two of the
three NPC (0–1.5 ng/mL), all three of the NPB (2–4.5 ng/mL) and both
of the LALD (0.5–2.5 ng/mL) plasma samples (Fig. 3E). The ultimate
metabolite of the pathway, 3β,7β-diH-Δ5-BA was present in control and
carrier plasma (0.5–2 ng/mL), but at higher levels in NPC (19–50 ng/
mL), NPB (14–40 ng/mL) and in LALD (4.5–14 ng/mL) (Fig. 3B).
3.4.2. Acidic pathway:- 7-OC
Considering next the pathway from 7-OC, authentic standards are
available for 26H,7O-C and 3βH,7O-CA allowing their deﬁnitive iden-
tiﬁcation. 26H,7O-C is present in control and carrier plasma (≤0.5 ng/
mL) and is found to be elevated in NPC (1–2.5 ng/mL), NPB (1–2 ng/
mL) but not LALD (< 0.5 ng/mL) plasma (Fig. 5B). The 7-oxo acid,
26H,7O-CA, is present in plasma from healthy controls and carriers
(1–1.5 ng/mL) but greatly elevated in plasma from NPC (13.5–60.5 ng/
mL), NPB (39–60 ng/mL) and LALD (9.5–52 ng/mL) (Fig. 5C). An au-
thentic standard is not available for 3β,24-dihydroxy-7-oxocholest-5-
en-26-oic acid (3β,24-diH,7O-CA), however, based on exact mass, re-
tention time and MS3 spectra it was presumptively identiﬁed in two of
the three NPC (0–0.5 ng/mL), all three NPB (0.5–1.5 ng/mL) and both
LALD (1–3 ng/mL) plasma samples (Fig. 5D, see Fig. 4G in Ref. [30]).
3β,24-diH,7O-CA was absent or of very low abundance in control and
carrier plasma samples (< 0.2 ng/mL). No authentic standard was
available for 3βH,7O-Δ5-BA. It was presumptively identiﬁed in control
and carrier (≤0.5 ng/mL), NPC (1.5–6.5 ng/mL), NPB (2–6.5 ng/mL)
and LALD (1–5.5 ng/mL) plasma (Fig. 5E, see Fig. 5D in Ref. [30]).
3.4.3. Metabolite ratios: 7O/7β
Unlike the situation for 7-OC and 7β-HC which are in a con-
centration ratio of about 2.5 for both NPC and NPB patents, the 7β-
hydroxy acids, 3β,7β-diHCA and 3β,7β-diH-Δ5-BA, are more abundant
than their 3-oxo analogues 3βH,7O-CA and 3βH,7O-Δ5-BA in the ratio
of about 3.5 and 8 for the C27 (NPC, 3.5 ± 0.4; NPB, 3.1 ± 0.8) and
C24 (NPC, 9.2 ± 2.7; NPB, 6.6 ± 0.2) acids, respectively. Both ratios
are also greater than 1 for the LALD patients (C27, 1.1; C24, 3.43) and
carriers (C27, 3.1 ± 0.7; C24, 3.5 ± 1.9) and controls. In contrast to
the situation for 3β,5α,6β-triHCa, where concentrations are higher in
NPB than NPC plasma (see Supplemental Table S1) the concentration
ranges of the acids 3β,7β-diHCA and 3βH,7O-CA both overlap for the
two disorders. In NPB plasma other acids 3β-HCA, 3β,7α-diHCA and
7αH,3O-CA were higher in NPB than in NPC plasma, as was their
precursor 26-HC. An absence of a similar trend for 3β,7β-diHCA and
3βH,7O-CA suggests that their formation is not dependent on CYP27A1
activity, but rather substrate availability.
4. Discussion
The observation here and elsewhere of elevated levels of 3β,5α,6β-
triol and 7-OC in the lysosomal storage diseases NPC and NPB points to
their endogenous formation [22]. While 7-OC can be formed en-
zymatically from 7-DHC in SLOS [43], there is little convincing evi-
dence for the enzymatic formation of 5,6-EC, the precursor of 3β,5α,6β-
triol, hence it is likely that it is formed through free radical reactions in
vivo. The absence of high levels of 7-DHC in NPC and NPB also points to
the formation of 7-OC via in vivo free radical reactions.
4.1. Formation of 3β,5α,6β-triHBA
Until recently little was known about the metabolism of 5,6-EC. It is
established that 5,6-EC can be enzymatically converted to the
3β,5α,6β-triol by ChEH [35], but only in 2016 was it shown that the
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triol could be converted to the bile acid 3β,5α,6β-triHBA in man
[28,29]. A similar product has also been proposed to be generated in rat
[44,45], however, a description of the pathway from 3β,5α,6β-triol to
3β,5α,6β-triHBA has not previously been reported.
There are two major pathways of bile acid biosynthesis, the neutral
and acidic pathways, and two more minor pathways, the sterol 24-
hydroxylase and 25-hydroxylase pathways [37]. The neutral pathway is
initiated by 7α-hydroxylation of cholesterol by CYP7A1, but in the
metabolism of 3β,5α,6β-triol the absence of a 7α-hydroxy group in the
ultimate bile acid argues against operation of this pathway. The cho-
lesterol 24-hydroxylase pathway is also an unlikely route for 3β,5α,6β-
triol metabolism as this starts with a reaction catalysed by CYP46A1,
predominantly expressed in brain [37]. This leaves the acidic and 25-
hydroxylase pathways for biosynthesis of 3β,5α,6β-triHBA from
3β,5α,6β-triol. As in the present study we have identiﬁed most of the
intermediates in a novel branch of the acidic pathway from 3β,5α,6β-
triol to 3β,5α,6β-triHBA in plasma, it is highly likely that this is the
pathway followed (Fig. 4).
4.2. Formation of 3βH,7O-Δ5-BA and 3β,7β-diH-Δ5-BA
The metabolism of 7-OC has been the subject of greater interest than
that of 3β,5α,6β-triol [40,41,46], as the former compound is found in
atherosclerotic lesions [47]. 7-OC can be metabolised to 26H,7-OC and
3βH,7O-CA [40,41], hence it likely to also follow another branch of the
acidic pathway to generate 3βH,7O-Δ5-BA. The data reported here
conﬁrms this hypothesis as judged by the preponderance of relevant
pathway intermediates identiﬁed in plasma of NPC and NPB patients. 7-
OC can alternatively be converted to 7β-HC [5-8] and this oxysterol
may similarly fall into a related branch of the acidic pathway with the
formation of 3β,7β-diH-Δ5-BA. These 7-OC and 7β-HC branches of the
acidic may be interconvertible through HSD11B1 which can convert 7-
oxo to 7β-hydroxy groups and HSD11B2 which can catalyse the reverse
reactions (Fig. 4). In fact, in an early study Alvelius et al. identiﬁed both
3βH,7O-Δ5-BA and 3β,7β-diH-Δ5-BA as their sulphate and glycine
conjugates in urine of an NPC patient [26], although the plasma pattern
of oxysterols was apparently normal. In the present study, the ratio of 7-
oxo- to 7β-hydroxy-sterols may provide an insight into the activity of
HSD11B enzymes. HSD11B1 is the enzyme responsible for reducing 7-
OC to 7β-HC in mouse and man [5,7], while HSD11B2 can also catalyse
the reverse reaction [9]. The HSD11B1 enzyme also catalyses the re-
duction of cortisone to cortisol in man and of 11-dehydrocorticosterone
to corticosterone in mouse, the reduced metabolites being ligands to the
glucocorticoid receptor. On the other hand, HSD11B2 is the enzyme
that oxidises cortisol to cortisone and has a similar activity towards 7β-
HC and also 7β,25-dihydroxycholesterol [9,48,49]. Data from the pre-
sent study indicates that as the acidic pathway proceeds the ratio of 7β-
hydroxy to 7-oxo metabolites increase, this is true for patients, controls
and carriers. This may be explained by the HSD11B reductase having a
dominant eﬀect over the oxidase as the pathway descends.
HSD11B2 also has activity towards 3β,5α,6β-triol, oxidising it to the
oncometabolite 3β,5α-diHC-6O, while HSD11B1 catalyses the reverse
reaction [11]. It appears that the enzymes ChEH, HSD11B1 and
HSD11B2 and CYP27A1 sit at a fulcrum balancing the formation from
5α,6-EC of the tumour suppressor DDA and from 5,6-EC, through
3β,5α,6β-triol, the oncometabolite 3β,5α-diHC-6O or the bile acid
3β,5α,6β-triHBA. It should also be noted that 26H,7O-C activates the
Hh signalling pathway, constitutive activation of which is linked to
tumorigenesis further connecting the HSD11B and CYP27A1 enzymes
to oncology.
In light of the low number of patient samples analysed the diag-
nostic value of bile acid precursors can only be speculated on. However,
the high abundance of the C27 acids 3β,5α,6β-triHCa, 3β,7β-diHCA
(Figure 3D) and 3βH,7O-CA (Fig. 5C) in NPC and NPB plasma suggests
that these three acids in combination may diagnose these disorders. It
may not be possible to distinguish these diseases from LALD as the three
acids are elevated in this disorder also.
5. Conclusion
In man, most of the primary bile acids are synthesised in the liver
through the neutral pathway of bile acid biosynthesis. The acidic
pathway can proceed extrahepatically [37], while quantitatively less
important in adult this pathway may be dominant in neonates [50]. We
show here that novel branches of the acidic pathway, starting from
oxysterols formed non-enzymatically, are important for the formation
of unusual bile acids in patients with lysosomal storage disease. In
healthy controls, the acidic pathway also proceeds to generate unusual
7β-hydroxy and 7-oxo bile acids but these are quantitatively minor.
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